Tirzepatide is the second act of the GLP-1 revolution — and by the numbers, the stronger one. Sold as Zepbound (FDA-approved for weight loss) and Mounjaro (approved for type 2 diabetes), it works on two gut-hormone pathways at once: GLP-1, like semaglutide, plus GIP, a second hormone involved in appetite and fat metabolism.
Why the dual mechanism matters
Semaglutide mimics one satiety hormone; tirzepatide mimics two. In practice that translated into the strongest clinical trial results the weight-loss field has ever produced: SURMOUNT-1 averaged ~20–22% body weight loss over 72 weeks at the top dose. And in 2025, the first true head-to-head trial — SURMOUNT-5 — settled the debate on averages: tirzepatide patients lost roughly 20% of body weight versus roughly 14% on semaglutide.
Interestingly, many patients also report the nausea is a touch milder — possibly a GIP effect — though experiences vary.
What treatment looks like
Identical rhythm to semaglutide: labs and history first, then a weekly self-injection with the dose stepped up gradually over about five months. Expect 12–18+ months of treatment, with most of the loss in the first year, then a maintenance decision.
The cost picture shifted in patients’ favor when the manufacturer began selling Zepbound directly in single-dose vials at $349–$499/month cash — often undercutting what compounded versions used to cost, with none of the sourcing questions.
The honest trade-offs
Same fundamentals as every GLP-1: it works while you take it (the SURMOUNT-4 stop study showed about half the weight returning within a year of quitting), nausea is the toll at each dose increase, and rapid weight loss shows in your face. Patients finishing their weight-loss phase commonly turn to dermal fillers for facial volume, and CoolSculpting or Emsculpt NEO for the stubborn-spot cleanup that medication alone doesn’t do.
Weighing the two drugs? Our semaglutide vs. tirzepatide comparison covers results, price, side effects, and how to actually choose.